利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.026 秒)

    Nanoparticles for delivery of a pharmacologically active agent
    6.
    发明申请
    Nanoparticles for delivery of a pharmacologically active agent 审中-公开
    用于递送药理活性剂的纳米颗粒

    公开(公告)号：US20060280798A1

    公开(公告)日：2006-12-14

    申请号：US10577973

    申请日：2004-11-03

    申请人： Barbara Ensoli

    发明人： Barbara Ensoli

    IPC分类号： A61K39/21 ,  A61K9/14

    CPC分类号： A61K9/167 ,  A61K9/5052 ,  A61K48/00 ,  C12N15/88

    摘要： Core-shell nanoparticles comprising: (a) a core which comprises a water insoluble polymer or copolymer, and (b) a shell which comprises a hydrophilic polymer or copolymer; said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble styrenic, acrylic or methacrylic monomer and specific hydrophylic monomers or copolymers.

    摘要翻译： 核 - 壳纳米颗粒包含：（a）包含水不溶性聚合物或共聚物的芯，和（b）包含亲水性聚合物或共聚物的壳; 所述纳米颗粒可通过在水溶液中包含至少一种水不溶性苯乙烯，丙烯酸或甲基丙烯酸单体和特定亲水单体或共聚物的混合物的乳液聚合获得。

    Compositions of antigens bound to HIV-1 Tat, fragments or derivatives thereof
    8.
    发明授权
    Compositions of antigens bound to HIV-1 Tat, fragments or derivatives thereof 失效
    与HIV-1 Tat，其片段或衍生物结合的抗原组成

    公开(公告)号：US07811573B2

    公开(公告)日：2010-10-12

    申请号：US10485180

    申请日：2002-07-26

    申请人： Barbara Ensoli

    发明人： Barbara Ensoli

    IPC分类号： A61K39/38 ,  A61K39/12 ,  A61K39/21 ,  A61K39/00 ,  A61K39/385

    CPC分类号： C07K14/005 ,  A61K39/39 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55516 ,  C12N2740/16322 ,  Y02A50/412

    摘要： The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selectively deliver these antigen(s) as well as active compounds to dendritic cells, endothelial cells and macrophages, due to its capability of targeting these A PC and of activating their maturation and functions and of increasing Th-1 type immune responses as an adjuvant. Therefore, due to these characteristics and to the distribution of these cells in the body (during physiological and pathological disorders), biologically active Tat, fragments or derivates thereof containing the RGD region, can be used for preventive, therapeutic and/or diagnostic purposes for HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumors.

    摘要翻译： 本发明涉及一种用于预防和/或治疗预防和/或治疗和/或诊断艾滋病毒/艾滋病，其他感染性疾病，炎症和血管生成疾病和肿瘤的方法，其利用生物活性的HIV-1 Tat蛋白，片段或衍生物 作为具有以下特征中的一个或多个的模块：抗原，佐剂和靶向递送系统到特定抗原呈递细胞，包括树突状细胞，内皮细胞和巨噬细胞。 特别地，据称Tat可以仅以其生物活性形式用作与一种或多种其它抗原组合的抗原，以引发或增强针对其自身以及其他抗原的保护性免疫应答和/或选择性地递送这些 抗原以及由树突状细胞，内皮细胞和巨噬细胞组成的活性化合物，由于其能够靶向这些A PC并激活其成熟和功能以及增加作为佐剂的Th-1型免疫应答。 因此，由于这些特征和这些细胞在体内的分布（在生理和病理障碍期间），含有RGD区的生物活性的Tat，其片段或衍生物可用于预防，治疗和/或诊断目的 艾滋病毒/艾滋病，其他传染病，炎症和血管生成疾病和肿瘤。